CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 54 enrolled
Drug / intervention
Nevirapine, FTC, and Tenofovirdrug
Likely dose
Nevirapine, FTC, and Tenofovir 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00344461
NCT00344461Phase 4Completed
CompareCT.gov

Cell Cycle Independent Antiretroviral Therapy: Combination of Nevirapine, FTC, and Tenofovir

University of Maryland, Baltimore·interventional·Posted Jun 26, 2006·Updated Nov 1, 2021

In Brief

A Phase 4 clinical trial evaluating Nevirapine, FTC, and Tenofovir for HIV. Completed, enrolled 54 participants across 1 site.

Detailed Summary

Open label, two year study of the clinical efficacy of the combination of FTC, Tenofovir, and Nevirapine. Sixty HIV infected patients without previous exposure to antiretroviral therapy will be enrolled. Study will include a pharmacokinetic substudy to evaluate the interaction of FTC and Nevirapine. Truvada may be used.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesUnited States
CollaboratorsBoehringer Ingelheim

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 26, 2006
Enrollment StartMar 1, 2004
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 20.0 years ago

Interventions

Nevirapine, FTC, and Tenofovirdrug

One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.